Our results indicate that montelukast exerts a chemopreventive effect on pancreatic cancer via the LTD4–CYSLTR1 axis and has potential for treatment of pancreatic carcinogenesis. Here, CYSLTR1 is linked to familial pancreatic carcinoma.